<DOC>
	<DOCNO>NCT00540553</DOCNO>
	<brief_summary>This research study first administration GSK971086 human . The purpose study assess safety tolerability GSK971086 , well , much GSK971086 blood different dos</brief_summary>
	<brief_title>Study Test Safety , Tolerability Blood Levels GSK971086 After 1 Dose &amp; 7 Days Dosing Healthy Adult Males</brief_title>
	<detailed_description />
	<criteria>Males 18 50 year age ( inclusive ) , time signing informed consent form . Healthy , determine Investigator , base medical evaluation perform Screening Period include medical history , physical examination , clinical laboratory test , cardiac monitoring . Subjects must agree use acceptable method contraception describe protocol . These criterion must follow time first dose study drug completion Final Safety PK Visit Followup Period . Body weight Body Mass Index ( BMI ) within range define protocol . Subject able understand comply protocol requirement , instruction , protocolstated restriction , include list informed consent form . Subject give informed consent participate study indicate provide sign dated write informed consent form prior study procedure . Subjects history clinically significant endocrine , gastrointestinal , hepatic , cardiovascular , neurological , haematological , immunological , renal , respiratory , genitourinary abnormality disease . Subjects history time past coronary artery disease , congestive heart failure , angina , myocardial infarction , cardiac surgery , valvular heart disease , clinically significant arrhythmia , dyspnea , pulmonary edema , stroke , transient ischemic attack . ECG exclusion criterion define protocol . Subjects history malignancy complete remission least 5 year , 1 year nonmelatonomatous skin carcinoma . Subjects value outside specify range protocol follow Key Clinical Laboratory Tests must exclude study : liver function test , renal function , electrolytes , metabolic , muscle haematology . Prostate Specific Antigen ( PSA ) &gt; 3.0ng/mL Screening subject family history early onset prostate cancer multiple member prostate cancer . History serious psychological disorder schizophrenia , uncontrolled bipolar disorder , suicidal behaviour . History drug alcohol abuse within 5 year prior Screening Period . Positive test illicit drug alcohol Screening assessment . A minimum list illicit drug screen list protocol . History regular alcohol consumption average &gt; 14 drinks/week within 12 month prior Screening Period . A positive test Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface antigen , Hepatitis C antibody upon screen , time prior Screening Period . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study drug , however , use acetaminophen , ibuprofen , naproxen allow , describe protocol . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study drug . History drug allergy , opinion Investigator , contraindicate participation . Where participation study would result donation blood excess 500mL within 56 day period . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study drug checkout clinic last day Treatment Period . Unwillingness adhere study Lifestyle Guidelines describe protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>SARM ,</keyword>
	<keyword>FTIH ,</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>